Article Text
Abstract
Proton pump inhibitor (PPI) use is becoming increasingly common. Although the toxicity profiles of PPIs are not well understood particularly in children, PPIs have been associated with increased risks of gastrointestinal and respiratory tract infection, vitamin B12 deficiency, hypomagnesaemia, bone fractures, and rebound hyperacidity after discontinuation. Prescribers should take into account that PPI uses pose toxicity risks, which remain to be fully characterised in infants and children.
- gastroesophageal reflux
- proton pump inhibitors
- safety
- adverse events
- children
Statistics from Altmetric.com
Footnotes
Funding The clinical research of PDB is supported by the Agency for Innovation by Science and Technology in Flanders (IWT) through the SAFE-PEDRUG Project (IWT/SBO 130033).
Competing interests None declared.
Provenance and peer review Commissioned; externally peer reviewed.